Prostaglandins

A new class of aqueous outflow agents

Carol B Toris, C. B. Camras

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The prostaglandin F(2α) analog, latanoprost, has been approved for the treatment of glaucoma in the United States. This is a new class of glaucoma agents that reduces intraocular pressure by increasing uveosclera outflow. Latanoprost is well tolerated, has few side effects, and maintains its efficacy over time. It is additive to other well established glaucoma medications, including timolol, acetazolamide, epinephrine, and pilocarpine. It has the unusual side effect of darkening the iris color in some patients with concentric heterochromia. This effect seems to be a cosmetic problem only, although further investigations are needed for confirmation.

Original languageEnglish (US)
Pages (from-to)335-355
Number of pages21
JournalOphthalmology Clinics of North America
Volume10
Issue number3
StatePublished - Oct 29 1997

Fingerprint

latanoprost
Prostaglandins A
Glaucoma
Synthetic Prostaglandins F
Timolol
Acetazolamide
Pilocarpine
Iris
Intraocular Pressure
Cosmetics
Epinephrine
Color
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Prostaglandins : A new class of aqueous outflow agents. / Toris, Carol B; Camras, C. B.

In: Ophthalmology Clinics of North America, Vol. 10, No. 3, 29.10.1997, p. 335-355.

Research output: Contribution to journalReview article

@article{94d50f9314344636b91dc8e14447b9dc,
title = "Prostaglandins: A new class of aqueous outflow agents",
abstract = "The prostaglandin F(2α) analog, latanoprost, has been approved for the treatment of glaucoma in the United States. This is a new class of glaucoma agents that reduces intraocular pressure by increasing uveosclera outflow. Latanoprost is well tolerated, has few side effects, and maintains its efficacy over time. It is additive to other well established glaucoma medications, including timolol, acetazolamide, epinephrine, and pilocarpine. It has the unusual side effect of darkening the iris color in some patients with concentric heterochromia. This effect seems to be a cosmetic problem only, although further investigations are needed for confirmation.",
author = "Toris, {Carol B} and Camras, {C. B.}",
year = "1997",
month = "10",
day = "29",
language = "English (US)",
volume = "10",
pages = "335--355",
journal = "Ophthalmology Clinics of North America",
issn = "0896-1549",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Prostaglandins

T2 - A new class of aqueous outflow agents

AU - Toris, Carol B

AU - Camras, C. B.

PY - 1997/10/29

Y1 - 1997/10/29

N2 - The prostaglandin F(2α) analog, latanoprost, has been approved for the treatment of glaucoma in the United States. This is a new class of glaucoma agents that reduces intraocular pressure by increasing uveosclera outflow. Latanoprost is well tolerated, has few side effects, and maintains its efficacy over time. It is additive to other well established glaucoma medications, including timolol, acetazolamide, epinephrine, and pilocarpine. It has the unusual side effect of darkening the iris color in some patients with concentric heterochromia. This effect seems to be a cosmetic problem only, although further investigations are needed for confirmation.

AB - The prostaglandin F(2α) analog, latanoprost, has been approved for the treatment of glaucoma in the United States. This is a new class of glaucoma agents that reduces intraocular pressure by increasing uveosclera outflow. Latanoprost is well tolerated, has few side effects, and maintains its efficacy over time. It is additive to other well established glaucoma medications, including timolol, acetazolamide, epinephrine, and pilocarpine. It has the unusual side effect of darkening the iris color in some patients with concentric heterochromia. This effect seems to be a cosmetic problem only, although further investigations are needed for confirmation.

UR - http://www.scopus.com/inward/record.url?scp=0030880802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030880802&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 335

EP - 355

JO - Ophthalmology Clinics of North America

JF - Ophthalmology Clinics of North America

SN - 0896-1549

IS - 3

ER -